- Renowned Clinical Authorities to Advise on Development of New Drug
Candidate to Treat Autoimmune Disease -
SAN MATEO, Calif., Feb. 5 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held drug development company, announced today that it has appointed the first five members of its Scientific Advisory Board for A-623, a peptide fusion protein licensed from Amgen in December 2007 for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. The scientific advisory board will include Jill Buyon, M.D., Betty Diamond, M.D., Kenneth Kalunian, M.D., David Wofsy, M.D., and Debra Zack, M.D., Ph.D.
"We are pleased to have recruited such an outstanding team of
internationally recognized experts in the field of autoimmune disease,"
said Paul F. Truex, President and Chief Executive Officer of Anthera
Pharmaceuticals, Inc. "All have made significant contributions to the
scientific understanding of lupus. The extraordinary magnitude of research
and clinical expertise assembled on this board will be invaluable as we
advance our clinical development programs for A-623."
-- Jill Buyon, M.D. is Professor of Medicine, New York University School
of Medicine and Vice Chairman of the Department of Rheumatology at NYU
Hospital for Joint Diseases.
-- Betty Diamond, M.D. is Head of The Center for Autoimmune and
Musculoskeletal Disease at the Feinstein Institute for Medical
Research and is on the faculty at Albert Einstein College of Medicine.
-- Kenneth Kalunian, M.D. is Professor of Medicine in the Division of
Rheumatology at the University of California, San Diego School of
-- David Wofsy, M.D. is Professor of Medicine and Microbiology/Immunology
at the University of California, San Francisco.
-- Debra Zack, M.D., Ph.D. is the Executive Director in Inflammation
Global Development at Amgen.
About AMG 623
AMG 623, which has completed Phase 1b studies in SLE patients, is a peptide fusion protein that binds to B-cell activating factor (BAFF). Anthera anticipates initiating Phase 2 studies in 2008. BAFF, a tumor necrosis factor family member, is critical for the survival and maturation of B cells. AMG 623 is a potent BAFF antagonist that is being developed as a treatment for B-cell dependent autoimmune diseases and is initially targeted for SLE.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a privately-held company committed to
developing and commercializing clinical pharmaceutical products that
address unmet medical needs of patients with life-threatening, chronic and
acute inflammatory and autoimmune diseases. The Company has acquired from
Eli Lilly and Company and Shionogi & Co. Ltd. worldwide rights (excluding
Japan) to a series of clinical and pre-clinical compounds that inhibit the
enzymatic activity of members of the phospholipase A2 (PLA2) family -- a
group of enzymes responsible for the release of arachidonic acid and
subsequent production of leukotrienes prostacyclins and other mediators of
inflammation. These highly potent compounds inhibit novel upstream steps
in the inflammation cascade and have the potential to address a variety of
diseases. The company has also acquired exclusive and worldwide rights to a
peptide fusion protein, A-623, for the treatment of systemic lupus
erythematosus (SLE) and other autoimmune diseases from Amgen. For more
information, please visit http://www.anthera.com.
Investor and Media Contact:
|SOURCE Anthera Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved